田海山

博士

长期从事生物制品工程化及研发工作,曾担任过多家制药企业生产部门负责人,熟悉基因工程产品的GMP认证、临床前研究的操作要点。作为主要技术人员参与国家 863 项目3项;承担国家重大新药创制项目1项并实现转化,参与2项;承担国家自然基金面上项目1项,参与3项;承担科技部科技型中小企业创新基金项目1项及多项省市级项目。发明专利授权9项,发表论文30余篇。获得省级科学技术奖一等、二等奖各1项,获得浙江省“151人才工程”第二层次及温州市“551人才工程”第一层次培养人员。

承担科研项目情况

1. 国家科技重大专项-新药创制项目,重组人酸性成纤维细胞生长因子改构体治疗糖尿病足新药临床前研究(主持)

2. 国家自然基金,bFGF对氧化应激相关酶的调控及其在促糖尿病皮肤创面修复中的作用(主持)

3. 科技型中小企业技术创新基金项目,重组人角质细胞生长因子-2滴眼液临床前研究(主持)

代表性论著

1.Shen Wang, Yong Li, Chao Jiang, Haishan Tian. Fibroblast growth factor 9 subfamily and the heart. Appl. Microbiol. Biotechnol. 2018, 102: 605-613.

2.Shen Wang, Lin Haipeng, Zhao Tiantian, Huang Sisi, Fernig David G, Xu Nuo, Wu Fenfang, Zhou Mi, Chao Jiang, Haishan Tian. Expression and purification of an FGF9 fusion protein in E. coli, and the effects of the FGF9 subfamily on human hepatocellular carcinoma cell proliferation and migration. Appl. Microbiol. Biotechnol. 2017 Nov, 101(21).

3.Haishan Tian,Yang Zhao,Nazi Chen, et al. High production in E. coli of biologically active recombinant human fibroblast growth factor 20 and its neuroprot ecti veeffects. Appl Microbiol Biotechnol, 2016, 100(7): 3023-3034.

4.Yuanhu Xuan#, Lisha Chi#, Haishan Tian#, et al. The activation of the NF-κB-JNKpathway is independent of thePI3K-Rac1-JNK pathway involved in the bFGF-regulated human fibroblast cell migration. Journal of Dermatological Science, 2016, 82(1): 28-37.

5.XuechaoJia, HaishanTian#, et al. High-Efficiency Expression of TAT-bFGF Fusion Protein in Escherichia coli and the Effect on Hypertrophic Scar Tissue. PLOS ONE, 2015,10(2): e0117448.

6.Zhuofeng Lin, Haishan Tian, et al. Adiponectin Mediates the Metabolic Effects of FGF21 on Glucose Homeostasis and Insulin Sensitivity in Mice. CellMetabolism, 2013, 17: 779–789.

微信扫一扫